Global DDI Solutions

Global DDI Solutions

Global DDI Solutions (GDDIS) was founded in 2022 by Prof. Dr. David Burger and Mrs. Alice Posthumus-Plantinga to develop a suite of world-leading drug-drug interactions (DDIs) resources and educational programs to support better quality prescribing for patients.

GDDIS aims at recording the interactions of drugs treating various diseases and for that purpose establishing various Drug Interactions tools to provide drug-drug interaction resources powered by DDI databases. These databases are accessible via disease-specific DDI websites (see below) and may be used to enable rapid screening of DDIs.


The user-friendly interface of our online DDI Managers ® allows you to access a pharmacological database of potential drug-drug interactions, alerting you to possible interactions and protecting your patients from adverse drug-drug events. The tools facilitates interaction checks specifically targeted at antifungal drugs and includes tailored advice on managing these interactions.

Covid-19 DDI Checker Platform

The COVID-19 Interactions Interface, developed in partnership with Radboud University Medical Center Nijmegen, is a comprehensive DDI tool specifically for Dutch medical health professionals.

The tool provides a user-friendly pharmacological database of potential drug-drug interactions with Nirmatrelvir + Ritonavir (Paxlovid®), alerting practitioners to potential interactions and protecting patients from adverse drug-drug events. Nirmatrelvir + Ritonavir is an antiviral medicine that works by stopping the virus that causes coronavirus (COVID-19) from growing and spreading in the body. While research with Nirmatrelvir+Ritonavir has shown it to reduce hospital admissions and/or mortality in high-risk groups, it is known to have several drug-drug interactions.

DDI Manager® Prostate Cancer

We’re are delighted to announce that the new Prostate Cancer DDI Manager has been added to our suite of leading DDI tools. This comprehensive up-to-date resource contains DDI Management recommendations for 9 prostate cancer agents and approximately 1,000 co-medications. Prostate cancer predominantly affects older men, who often have multiple comorbidities, with polypharmacy being common.

Several prostate cancer agents can be a ‘perpetrator’ or ‘victim’ of DDIs due to inducing CYP450 enzymes and/or membrane transporters. Acid-reducing agents can influence the pH-dependent absorption of prostate cancer agents, especially abiraterone. Adding treatment for prostate cancer to existing polypharmacy increases the risk of drug-drug interactions (DDIs).

To counteract these risks, the Prostate Cancer DDI Manager was conceived and developed in partnership with leading experts in the field.

DDI Manager® Lung Cancer

Patients with lung cancer have an increased risk for the development of drug-drug interactions (DDIs) due to increased comorbidities and the risk of polypharmacy.
There is a growing body of evidence to show that DDIs in these patients have significant clinical consequences.
To counteract this risk, we proudly present our new specialized Lung Cancer DDI Manager – a cutting-edge tool developed by GDDIS in partnership with leading experts in the field, launched in November 2023.
This comprehensive, up-to-date resource provides you with accurate, independent data on pharmacokinetics and therapeutic monitoring of drugs used to treat lung cancer.

DDI Manager® Fungal Infections

Patients who develop invasive fungal infections are often immunocompromised, with polypharmacy being common.
With this polypharmacy comes an increased risk of drug-drug interactions.
To counteract this risk, we proudly announce our new Antifungal DDI Manager – a cutting-edge tool developed in
partnership with leading experts in the field.
This comprehensive, up-to-date resource will provide accurate, independent data on antifungal pharmacokinetics
and therapeutic drug monitoring.